Academic Appointments

  • Visiting Instructor/Lecturer, Ophthalmology

Contact

  • Academic
    pooja195@stanford.edu
    University - Other Teaching/Research Department: Ophthalmology Research/Clinical Trials Position: Visiting Instructor/Lecturer

Additional Info

All Publications

  • Longitudinal foveal adaptive optics scanning laser ophthalmoscopy in multiple sclerosis Hargrave, A., Buickians, D., Navarro, S., Parthasarathi, P., Kipp, L., Han, M., Zavalla, G., Kowalski, B., Dubra, A., Moss, H. E. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2024

    View details for Web of Science ID 001313316200178

  • In Vivo OCT Imaging of Muller and Macrophage-Like Cells in the Retinas of Patients with and without MS and related diseases Elizabeth, S., Navarro, V., Han, M., Kipp, L., Hargrave, A., Parthasarathi, P., Sylvestre-Bouchard, A., Dubra, A., Moss, H. E. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2024

    View details for Web of Science ID 001312227704062

  • Comparison of comorbidities in people with eye pain due to dry eye and eye pain due to other ocular causes in a tertiary care Neuro-Ophthalmolgy practice Parthasarathi, P., Moss, H., Navarro, S. ASSOC RESEARCH VISION OPHTHALMOLOGY INC. 2024

    View details for Web of Science ID 001312227700156

  • Review of evidence for treatments of acute non arteritic anterior ischemic optic neuropathy. Eye (London, England) Parthasarathi, P., Moss, H. E. 2024

    Abstract

    OBJECTIVE: To review treatment modalities that have been studied in acute nonarteriticanterior ischemic optic neuropathy (NAION).METHODS: We performed a comprehensive literature search of English language publications in the last 5 years, with human species and NAION. Articles were reviewed to identify those that described original research on treatment of acute NAION. Study type, setting, duration, interventions, and results were extracted and articles were reviewed for biases and limitations.RESULTS: We identified 22 kinds of treatment varying by compound and modality. These include topical, intravitreal, and systemic drugs as well as surgical approaches. Evidence for efficacy ranges from expert opinion to randomized control trials.CONCLUSIONS: Although several treatments are utilized in practice, none of these have high quality evidence of efficacy to improve visual outcomes. Continued collaborative research is necessary to complete high quality studies in order identify effective therapies for this rare and blinding disease.

    View details for DOI 10.1038/s41433-024-03136-8

    View details for PubMedID 38778140

https://orcid.org/0009-0004-0363-2940